NT-proBNP in the Early Convalescent Phase after High-Risk Myocardial Infarction Is Associated with Adverse Cardiovascular Outcomes: the PARADISE-MI Trial
Journal of Cardiac Failure · 2026-03 · 32 (3) · 586-595
DOI: 10.1016/j.cardfail.2025.03.018 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Cardiac Failure, 2026-03. Verfasst von Karola S Jering und 18 weiteren Autor:innen. Beteiligte Einrichtung: Cardiovascular Division, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts. Electronic address: kjering@bwh.harvard.edu. Hauptthemen laut MEDLINE: Myocardial Infarction, Peptide Fragments, Natriuretic Peptide, Brain, Heart Failure. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: Novartis.
Abstract (Originalsprache)
BACKGROUND: N-terminal pro-B-type natriuretic peptide (NT-proBNP) is associated with heart failure (HF) hospitalizations and death when measured during a myocardial infarction (MI). However, NT-proBNP concentrations change following the initial ischemic insult and less is known about the prognostic importance of NT-proBNP in the early convalescent phase. METHODS: PARADISE-MI randomized 5661 patients with MI complicated by LVEF ≤40% and/or pulmonary congestion to sacubitril/valsartan or ramipril. Patients with available week 2 NT-proBNP concentrations and without-incident HF between randomization and week 2 (n = 1062) were analyzed. Associations of week 2 NT-proBNP with subsequent clinical outcomes were evaluated in landmark analyses using Cox models adjusted for clinical characteristics, including LVEF, baseline NT-proBNP and atrial fibrillation. RESULTS: Median 2-week NT-proBNP concentration was 1391 [676-2507] ng/L. Patients in the highest NT-proBNP quartile (≥2507 ng/L) were older, had lower left ventricular ejection fraction (LVEF) and estimated glomerular filtration rate (eGFR), higher Killip class, and more atrial fibrillation. Higher NT-proBNP concentrations were independently associated with greater risk of cardiovascular death or incident HF (adjusted hazard ratio [aHR], 1.65 per doubling of NT-proBNP; 95% confidence interval [CI], 1.31-2.09), HF hospitalization (aHR, 1.87; 95% CI, 1.38-2.54), recurrent myocardial infarction (aHR, 1.46; 95% CI, 1.09-1.95) and all-cause death (aHR, 1.85; 95% CI, 1.35-2.53). CONCLUSIONS: Patients with elevated NT-proBNP concentrations approximately 2 weeks after a high-risk myocardial infarction are at heightened risk of incident HF, recurrent coronary events, and death independent of baseline NT-proBNP concentrations and clinical characteristics. Elevations in NT-proBNP concentrations in the early convalescent phase may assist in risk stratification and the identification of patients in need of more advanced preventive treatment approaches.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cardiovascular Division, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts. Electronic address: kjering@bwh.harvard.edu.
- Cardiovascular Division, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts.
- Cardiovascular Division, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts; TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, and Harvard Medical School, Boston, Mass…
- Division of Cardiology, Duke University School of Medicine, Durham, North Carolina; Montreal, Quebec, Canada.
- Department of Cardiology, Copenhagen University Hospital-Rigshospitalet, Copenhagen, Denmark.
- Deutsches Herzzentrum der Charité (DHZC), Department of Cardiology, Angiology and Intensive Care Medicine; Charité Universitätsmedizin Berlin, Campus Benjamin-Franklin (CBF), Berlin, Germany.
Förderung
- Novartis
Zitieren
APA
Jering, K. S., Claggett, B. L., Braunwald, E., Granger, C. B., Køber, L., Landmesser, U., Lewis, E. F., Maggioni, A. P., Mann, D. L., McMurray, J. J., Mehran, R., Petrie, M. C., Prescott, M. F., Rouleau, J. L., Schou, M., Solomon, S. D., Steg, P. G., VON Lewinski, D., & Pfeffer, M. A. (2026). NT-proBNP in the Early Convalescent Phase after High-Risk Myocardial Infarction Is Associated with Adverse Cardiovascular Outcomes: the PARADISE-MI Trial. Journal of Cardiac Failure, 32(3), 586-595. https://doi.org/10.1016/j.cardfail.2025.03.018
Vancouver
Jering KS, Claggett BL, Braunwald E, Granger CB, Køber L, Landmesser U, et al. NT-proBNP in the Early Convalescent Phase after High-Risk Myocardial Infarction Is Associated with Adverse Cardiovascular Outcomes: the PARADISE-MI Trial. Journal of Cardiac Failure. 2026;32(3):586-595. doi:10.1016/j.cardfail.2025.03.018
BibTeX
@article{Jering2026,
author = {Jering, Karola S and Claggett, Brian L and Braunwald, Eugene and Granger, Christopher B and Køber, Lars and Landmesser, Ulf and Lewis, Eldrin F and Maggioni, Aldo P and Mann, Douglas L and McMurray, John Jv and Mehran, Roxana and Petrie, Mark C and Prescott, Margaret F and Rouleau, Jean L and Schou, Morten and Solomon, Scott D and Steg, Philippe Gabriel and VON Lewinski, Dirk and Pfeffer, Marc A},
title = {NT-proBNP in the Early Convalescent Phase after High-Risk Myocardial Infarction Is Associated with Adverse Cardiovascular Outcomes: the PARADISE-MI Trial},
journal = {Journal of Cardiac Failure},
year = {2026},
volume = {32},
number = {3},
pages = {586--595},
doi = {10.1016/j.cardfail.2025.03.018}
}
EUVIMED